Cargando…
Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients
BACKGROUND: Increasing evidence suggests that severe skeletal muscle index (SMI) loss (sarcopenia) is associated with poor overall survival in metastatic colorectal cancer patients, but its mechanisms are unknown. We recently found, using data of the randomized phase 3 CAIRO3 study, that SMI loss wa...
Autores principales: | Kurk, Sophie, Peeters, Petra, Stellato, Rebecca, Dorresteijn, B., de Jong, Pim, Jourdan, Marion, Creemers, Geert‐Jan, Erdkamp, Frans, de Jongh, Felix, Kint, Peter, Simkens, Lieke, Tanis, Bea, Tjin‐A‐Ton, Manuel, Van Der Velden, Ankie, Punt, Cornelis, Koopman, Miriam, May, Anne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711417/ https://www.ncbi.nlm.nih.gov/pubmed/31094083 http://dx.doi.org/10.1002/jcsm.12436 |
Ejemplares similares
-
Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial
por: Kurk, Sophie A., et al.
Publicado: (2019) -
Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients
por: Kurk, Sophie A, et al.
Publicado: (2019) -
Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients
por: Kurk, Sophie A., et al.
Publicado: (2018) -
The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer
por: Derksen, Jeroen W.G., et al.
Publicado: (2020) -
Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer
por: Derksen, Jeroen W G, et al.
Publicado: (2019)